Star Therapeutics patched together a $125 million Series D in what it thinks is pharma’s next big therapeutic category. The South San Francisco startup expects the funds to add a few years of runway and get its sole clinical-stage drug most of the way through a Phase 3 trial in von Willebrand disease while also expanding into other disorders, CEO Adam Rosenthal told Endpoints News...

The biotech began Phase 3 testing of an experimental medicine for Von Willebrand disease in early September. Star Therapeutics has raised $125 million in new venture funding that will help propel its experimental blood disease drug through late-stage testing. Initially formed as a “hub-and-spoke” biotech intending to build single-drug offshoots, Star is now primarily focused on a singular program for...

A hefty $125 million in new financing has been written in the stars for Star Therapeutics through an oversubscribed series D funding round. The series D was co-led by Sanofi Ventures and Viking Global Investors, with support from over a dozen existing investors including Sofinnova, Blue Owl Capital and RA Capital Management. New investors such as Janus Henderson...

Earlier this week, Star Therapeutics’ von Willebrand disease candidate – VGA039 – was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). While it is the most common inherited bleeding disorder and affects about 1% of the population, you don’t hear about von Willebrand disease every day. With Star Therapeutics’ candidate getting some recognition from the FDA...